Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202.

Autor: Bednasz CJ; AIDS Clinical Trials Group Pharmacology Specialty Laboratory, New York State Center of Excellence in Bioinformatics and Life Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA amabile@buffalo.edu., Venuto CS; AIDS Clinical Trials Group Pharmacology Specialty Laboratory, New York State Center of Excellence in Bioinformatics and Life Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.; Center for Health + Technology, University of Rochester, Rochester, New York, USA., Ma Q; AIDS Clinical Trials Group Pharmacology Specialty Laboratory, New York State Center of Excellence in Bioinformatics and Life Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA., Daar ES; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and the University of California, Los Angeles, California, USA., Sax PE; Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA., Fischl MA; University of Miami School of Medicine, Miami, Florida, USA., Collier AC; University of Washington School of Medicine and Harborview Medical Center, Seattle, Washington, USA., Smith KY; ViiV Healthcare, Research Triangle Park, North Carolina, USA., Tierney C; Statistical Data Analysis Center, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA., Acosta EP; Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama, USA., Mager DE; Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA., Morse GD

Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2019 Mar 27; Vol. 63 (4). Date of Electronic Publication: 2019 Mar 27 (Print Publication: 2019).

Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications.

Autor: Bednasz CJ; AIDS Clinical Trials Group Pharmacology Specialty Laboratory, New York State Center of Excellence in Bioinformatics and Life Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA., Venuto CS; AIDS Clinical Trials Group Pharmacology Specialty Laboratory, New York State Center of Excellence in Bioinformatics and Life Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.; Center for Human Experimental Therapeutics, University of Rochester, Rochester, NY, USA., Ma Q; AIDS Clinical Trials Group Pharmacology Specialty Laboratory, New York State Center of Excellence in Bioinformatics and Life Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA., Morse GD; AIDS Clinical Trials Group Pharmacology Specialty Laboratory, New York State Center of Excellence in Bioinformatics and Life Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.

Publikováno v: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2017 Mar; Vol. 6 (2), pp. 135-139.

Recent advances in management of the HIV/HCV coinfected patient.

Autor: Bednasz CJ; School of Pharmacy & Pharmaceutical Sciences, University at Buffalo, 285 Kapoor Hall, Buffalo, New York 14214, USA; New York State Center of Excellence in Bioinformatics & Life Sciences, University at Bufalo, 701 Ellicott Street, Buffalo, New York 14203, USA., Sawyer JR; School of Pharmacy & Pharmaceutical Sciences, University at Buffalo, 285 Kapoor Hall, Buffalo, New York 14214, USA., Martinez A; Buffalo General Medical Center, University at Buffalo, Room. 617F, B Building, Buffalo, New York 14203, USA; Hepatology, Division of Gastroenterology, Hepatology & Nutrition, Erie County Medical Center, 462 Grider Street, Buffalo, New York 14215, USA., Rose PG; School of Pharmacy & Pharmaceutical Sciences, University at Buffalo, 285 Kapoor Hall, Buffalo, New York 14214, USA., Sithole SS; Translational Pharmacology Research Core, niversity at Buffalo, 701 Ellicott Street, Buffalo, New York 14203, USA., Hamilton HR; New York State Center of Excellence in Bioinformatics & Life Sciences, University at Bufalo, 701 Ellicott Street, Buffalo, New York 14203, USA; Immunodeficiency Services Clinic, Erie County Medical Center, 462 Grider Street, Buffalo, New York 14215, USA., Kaufman FS; Translational Pharmacology Research Core, NYS Center of Excellence in Bioinformatics & Life Sciences, University at Buffalo, 701 Ellicott Street, Buffalo, New York 14203-1101, USA., Venuto CS; Center for Human Experimental Therapeutics, University of Rochester Medical Center, 265 Crittenden Blvd. CU 420694, Rochester, New York 14642-0694, USA., Ma Q; School of Pharmacy & Pharmaceutical Sciences, New York State Center of Excellence in Bioinformatics & Life Sciences, University at Buffalo, 701 Ellicott Street, Buffalo, New York 14203, USA., Talal A; UBMD Center for Clinical Care & Research in Liver Disease, 875 Ellicott Street, Suite 6090, Buffalo, New York 14203, USA; Division of Gastroenterology, Hepatology and Nutrition, Clinical & Translational Research Center, 875 Ellicott Street, Suite 6090, Buffalo, New York 14203, USA., Morse GD; Pharmacy Practice (Medicine and Pediatrics), School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, 285 Kapoor Hall, Buffalo, New York 14214, USA; New York State Center of Excellence in Bioinformatics and Life Sciences, University at Buffalo, 701 Ellicott Street, Buffalo, New York 14203, USA.

Publikováno v: Future virology [Future Virol] 2015; Vol. 10 (8), pp. 981-997.